William Blair initiated coverage on shares of Allergan PLC (NYSE:AGN) in a research report sent to investors on Monday, The Fly reports. The firm issued a market perform rating on the stock.
AGN has been the subject of several other reports. Credit Suisse Group AG assumed coverage on shares of Allergan PLC in a research report on Monday, July 25th. They set an outperform rating and a $327.00 price target for the company. Vetr raised shares of Allergan PLC from a buy rating to a strong-buy rating and set a $285.60 price target for the company in a research report on Monday, July 25th. Zacks Investment Research lowered shares of Allergan PLC from a buy rating to a hold rating in a research report on Tuesday, July 26th. Leerink Swann increased their price target on shares of Allergan PLC from $272.00 to $294.00 and gave the company an outperform rating in a research report on Wednesday, July 27th. Finally, Mizuho increased their price target on shares of Allergan PLC from $232.00 to $246.00 and gave the company a neutral rating in a research report on Friday, August 5th. Seven investment analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the stock. Allergan PLC has an average rating of Buy and a consensus price target of $289.11.
Shares of Allergan PLC (NYSE:AGN) opened at 193.09 on Monday. Allergan PLC has a 12 month low of $184.50 and a 12 month high of $322.68. The company’s 50-day moving average is $214.61 and its 200 day moving average is $233.51. The company has a market capitalization of $72.42 billion, a price-to-earnings ratio of 5.41 and a beta of 1.08.
Allergan PLC (NYSE:AGN) last issued its earnings results on Wednesday, November 2nd. The company reported $3.32 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.65 by $0.33. Allergan PLC had a return on equity of 7.26% and a net margin of 93.74%. The business had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.73 billion. During the same quarter in the previous year, the company earned $3.48 earnings per share. The firm’s revenue was up 4.4% on a year-over-year basis. On average, equities research analysts anticipate that Allergan PLC will post $13.37 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 28th. Shareholders of record on Tuesday, February 28th will be issued a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a yield of 1.45%. This is a positive change from Allergan PLC’s previous quarterly dividend of $0.05.
In other news, CFO Maria Teresa Hilado acquired 1,422 shares of the firm’s stock in a transaction on Friday, November 11th. The shares were bought at an average price of $210.64 per share, for a total transaction of $299,530.08. Following the acquisition, the chief financial officer now owns 12,659 shares of the company’s stock, valued at approximately $2,666,491.76. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Brent L. Saunders acquired 5,250 shares of the firm’s stock in a transaction on Monday, November 21st. The stock was purchased at an average price of $189.13 per share, for a total transaction of $992,932.50. The disclosure for this purchase can be found here. 0.27% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Barnett & Company Inc. bought a new position in Allergan PLC during the first quarter valued at approximately $111,000. Livingston Group Asset Management CO operating as Southport Capital Management bought a new position in Allergan PLC during the second quarter valued at approximately $125,000. Trust Co. of Vermont raised its position in Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock valued at $126,000 after buying an additional 89 shares in the last quarter. Carroll Financial Associates Inc. raised its position in Allergan PLC by 68.7% in the third quarter. Carroll Financial Associates Inc. now owns 555 shares of the company’s stock valued at $127,000 after buying an additional 226 shares in the last quarter. Finally, Integrated Investment Consultants LLC raised its position in Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock valued at $137,000 after buying an additional 154 shares in the last quarter. Institutional investors own 89.21% of the company’s stock.
Allergan PLC Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Allergan PLC and related companies with MarketBeat.com’s FREE daily email newsletter.